IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Exploration of HIV Reservoirs (MUCOVIR)
This study has been completed.
Sponsor:
Objectif Recherche Vaccins SIDA
Information provided by (Responsible Party):
Objectif Recherche Vaccins SIDA
ClinicalTrials.gov Identifier:
NCT01019044
First received: November 24, 2009
Last updated: February 12, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Prospective study in HIV-1 infected patients with a plasma viral load below the limit of detection and stable for at least 5 years.
| Condition | Intervention |
|---|---|
| HIV-1 Infection | Procedure: Rectal mucosa biopsy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Virologic and Immunologic Evaluation of the Deep Viral Reservoirs in HIV-1 Infected Patients With Long Term Viral Suppression |
Resource links provided by NLM:
Further study details as provided by Objectif Recherche Vaccins SIDA:
Primary Outcome Measures:
- Quantification of the HIV-RNA plasma viral load using ultrasensible assay (limit of detection: 1 copy/ml) [ Time Frame: Single patient visit ]
Secondary Outcome Measures:
- Quantification of the HIV proviral DNA in the rectal mucosa biopsies and in the PPBMCs [ Time Frame: Single patient visit ]
- Quantitative, phenotypic and functional description of the long-term immune reconstitution in the rectal mucosa biopsies [ Time Frame: Single patient visit ]
- Quantification of HIV proviral DNA in the total CD4 lymphocytes [ Time Frame: Single patient visit ]
- Pharmacokinetics of the antiretroviral molecules in the rectal mucosa biopsies and in the blood [ Time Frame: Single patient visit ]
Biospecimen Retention: None Retained
Plasma and total blood samples A maximum of 15 rectal mucosa biopsy samples
| Enrollment: | 11 |
| Study Start Date: | May 2009 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Rectal mucosa biopsy
Rectal mucosa samples collection
|
Procedure: Rectal mucosa biopsy
Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
|
Detailed Description:
Evaluation of the mucosal HIV reservoirs (HIV-DNA quantification and distribution of the infected T lymphocytes in the gut mucosa associated lymphoid tissue compared to the blood in HIV-1 infected patients under antiretroviral treatment with an undetectable plasma viral load below the 50 copies/ml limit of detection for at least 5 years).
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV-1 infected patients followed in specialized infectious disease/HIV hospital department
Criteria
Inclusion Criteria:
- HIV-1 documented infection
- HIV-1 plasma viral load measurable before antiretroviral treatment initiation
- Patients treated with an antiretroviral combination containing a protease inhibitor and/or a non-nucleosidic reverse transcriptase inhibitor without any interruption since treatment initiation
- Patients with a stable plasma viral load below the limit of detection (HIV-RNA < 50 copies/ml since January 2006 and/or HIV-RNA < 200 copies/ml during the anterior period) under antiretroviral treatment for at least 5 years and for at least 90 % of the measures
Exclusion Criteria:
- Contraindication to the biopsy
- No ability or willingness to provide informed consent
- Concomitant treatment with antithrombotics or platelets antiaggregatory
- Patients co-infected with HCV and or HBV
- Patients who received an immunosuppressive treatment during 3 months prior enrollment (chemotherapy, radiotherapy, corticotherapy, splenectomy) or an immunotherapy during 5 years prior enrolment (IL-2, anti-HIV vaccine, IFN-alpha)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01019044
Please refer to this study by its ClinicalTrials.gov identifier: NCT01019044
Locations
| France | |
| Groupe Hospitalier Pitié-Salpêtrière | |
| Paris, France, 75013 | |
Sponsors and Collaborators
Objectif Recherche Vaccins SIDA
Investigators
| Principal Investigator: | Christine KATLAMA, MD | Groupe Hospitalier Pitié-Salpêtrière |
| Study Director: | François LECARDONNEL, MSc | ORVACS |
More Information
Publications:
| Responsible Party: | Objectif Recherche Vaccins SIDA |
| ClinicalTrials.gov Identifier: | NCT01019044 History of Changes |
| Other Study ID Numbers: |
ORVACS 009 |
| Study First Received: | November 24, 2009 |
| Last Updated: | February 12, 2013 |
Keywords provided by Objectif Recherche Vaccins SIDA:
|
HIV Viral reservoirs Viral load |
ClinicalTrials.gov processed this record on August 18, 2017